文献速递血液透析通路慢性静脉疾病

覆膜支架长度与透析患者中心静脉狭窄通畅率降低相关

Stent-Graft Length Is Associated with Decreased Patency in Treatment of Central Venous Stenosis in Hemodialysis Patients.
PubMed 文献 · Ann Vasc Surg · 2019-04-19

该单中心回顾性研究纳入29例因中心静脉闭塞性疾病置入Viabahn覆膜支架以维持透析通路的患者,技术成功率100%,中位随访24个月,6、12、24个月一期通畅率分别为92.9%、91.7%、80.0%,二期通畅率分别为96.4%、95.8%、93.3%;支架长度较长与再狭窄显著相关(P=0.002)。

要点

  • 覆膜支架治疗透析患者中心静脉狭窄的一期通畅率合理、二期通畅率优良。
  • 支架长度较长与远期通畅率较差显著相关(P=0.002)。
  • 4例(13.8%)出现症状性支架内再狭窄需二次干预,均见于原发狭窄50%–75%者。

核心结论

  • 覆膜支架用于透析患者中心静脉狭窄具有合理的一期通畅率和优良的二期通畅率,但支架长度较长与远期通畅率较差相关。

研究设计与样本

  • 单中心回顾性研究,纳入2014年4月至2016年12月因中心静脉闭塞性疾病置入覆膜支架以维持失效透析通路的患者29例。
  • 全部患者使用Viabahn覆膜支架,技术成功率100%。
  • 患者以女性为主(65.5%),平均年龄67.9±12.1岁,合并高血压86%、糖尿病76%、吸烟7%。
  • 86%有既往球囊扩张史,17/29(59%)有既往中心静脉导管置入史。
  • 最常置入的血管为右头臂静脉(28%),支架中位长度50毫米(范围25–100毫米),中位直径13毫米(范围9–13毫米)。

主要发现

  • 83%患者置入单枚支架,仅2例需置入多枚。
  • 中位随访24个月(范围6–41个月)。
  • 4/29(13.8%)出现症状性支架内再狭窄需二次干预,均发生于原发狭窄50%–75%的患者。
  • 与无再狭窄患者相比,较长支架与再狭窄显著相关(62.5厘米,四分位距[IQR]:0 vs. 50厘米,IQR:0,P=0.002)。
  • 6、12、24个月一期通畅率分别为92.9%、91.7%、80.0%,二期通畅率分别为96.4%、95.8%、93.3%;Kaplan-Meier分析30.5个月(95%CI:26.5–34.5个月)总一期通畅率估计为86.2%。

临床怎么用

  • 覆膜支架可用于透析患者中心静脉狭窄以维持通路,但选择支架时应尽量缩短支架长度以改善远期通畅。
  • 对原发狭窄50%–75%及置入较长支架者需加强随访监测支架内再狭窄。

局限性

  • 单中心回顾性设计,样本量仅29例,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Central venous occlusion may occur in hemodialysis patients, resulting in arm or facial swelling and failure of dialysis access. Endovascular management with balloon angioplasty or stenting has been described, but there are minimal data on the use of covered stents in this pathology. We sought to review a single institution's experience with the use of covered stents for central venous occlusive disease in hemodialysis patients. METHODS: A retrospective review of all patients undergoing placement of covered stents between April 2014 and December 2016 for central venous occlusive disease to preserve a failing dialysis access was performed. Patients' records were reviewed to identify demographics, medical comorbidities, operative variables, primary patency rates, and secondary interventions. RESULTS: A total of 29 patients were included in the analysis. Viabahn (W.L. Gore and Associates, Flagstaff, AZ) stent grafts were exclusively used in all patients. Technical success rate was 100%. The patients were predominantly female (65.5%), with a mean age of 67.9 ± 12.1 and medical comorbidities of hypertension (86%), diabetes (76%), and tobacco use (7%). The majority (86%) had prior angioplasty and 17 of 29 (59%) patients had previous central venous catheters. The right brachiocephalic vein was the most commonly stented vessel (28%). The median stent length and diameter used were 50 millimeters (range 25-100 millimeters) and 13 millimeters (range: 9-13 millimeters), respectively. The majority of patients (83%) received a single stent, with only 2 patients requiring more than one. Median follow-up was 24 months (range: 6-41 months). Four of 29 (13.8%) patients developed symptomatic stent restenosis requiring secondary intervention, all of which occurred in patients with primary stenosis between 50% and 75%. When compared to the patients without restenosis, longer stents were found to be significantly associated with restenosis (62.5 centimeters, interquartile range [IQR]: 0] vs. 50 centimeter, IQR: 0, P = 0.002). Primary patency rates were 92.9%, 91.7%, and 80.0% at 6, 12, and 24 months respectively. Secondary patency rates were 96.4%, 95.8%, and 93.3% at 6 months, 12 months, and 24 months, respectively. The overall primary patency rate was estimated at 86.2% using Kaplan-Meier analysis at 30.5 months (95% confidence interval: 26.5-34.5 months). CONCLUSIONS: Covered stent grafts have reasonable primary patency and excellent secondary patency when used for central venous stenosis in dialysis patients. Stent-graft length is associated with poorer long-term patency rates.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Boutrous ML, Alvarez AC, Okoye OT, et al. Stent-Graft Length Is Associated with Decreased Patency in Treatment of Central Venous Stenosis in Hemodialysis Patients. Ann Vasc Surg. 2019. PMID: 31009722. doi:10.1016/j.avsg.2019.01.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。